TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Outcomes for Multiple Morbidities Using Collaborative Group Clinics to Empower Older Patients
Brief Summary: The purpose of this study is to determine if group clinics help older veterans change behaviors with the goal of improving diabetes outcomes.


Options:
A: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care
B: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Arm Label: Patient Peer Support and Empowerment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient Peer Support and Empowerment | Intervention Type: BEHAVIORAL; Name: Patient Peer Support and Empowerment; Assigned to Arm(s): Patient Peer Support and Empowerment | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual care
C: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
D: Arm Label: Telemedicine case management; Type: EXPERIMENTAL; Interventions: Device: Telemedicine Unit (HTU) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: DEVICE; Name: Telemedicine Unit (HTU); Assigned to Arm(s): Telemedicine case management | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Outcomes for Multiple Morbidities Using Collaborative Group Clinics to Empower Older Patients
Brief Summary: The purpose of this study is to determine if group clinics help older veterans change behaviors with the goal of improving diabetes outcomes.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
C: Arm Label: care guide; Type: EXPERIMENTAL; Interventions: Behavioral: education and care guide | Arm Label: no care guide; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education only | Intervention Type: BEHAVIORAL; Name: education and care guide; Assigned to Arm(s): care guide | Intervention Type: BEHAVIORAL; Name: education only; Assigned to Arm(s): no care guide
D: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Outcomes for Multiple Morbidities Using Collaborative Group Clinics to Empower Older Patients
Brief Summary: The purpose of this study is to determine if group clinics help older veterans change behaviors with the goal of improving diabetes outcomes.


Options:
A: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): 1
C: Arm Label: Health coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): Health coaching
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Interactive Voice Response System | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-Led Group Clinic Visits | Intervention Type: BEHAVIORAL; Name: Interactive Voice Response System; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Nurse-Led Group Clinic Visits; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Outcomes for Multiple Morbidities Using Collaborative Group Clinics to Empower Older Patients
Brief Summary: The purpose of this study is to determine if group clinics help older veterans change behaviors with the goal of improving diabetes outcomes.


Options:
A: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care
B: Arm Label: Enhanced treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced treatment as usual plus adherence training | Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced treatment as usual plus CBT-AD | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual plus adherence training; Assigned to Arm(s): Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual plus CBT-AD; Assigned to Arm(s): CBT-AD
C: Arm Label: Geriatric Diabetes Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral | Arm Label: Atention Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Geriatric Diabetes Team Intervention
D: Arm Label: Active Control Group (ACG); Type: OTHER; Interventions: Device: Accu-Chek Aviva Glucose Meter | Arm Label: Structured Testing Group (STG); Type: EXPERIMENTAL; Interventions: Device: Accu-Chek 360° View Blood Glucose Analysis Tool, Device: Accu-Chek Aviva Glucose Meter | Intervention Type: DEVICE; Name: Accu-Chek 360° View Blood Glucose Analysis Tool; Assigned to Arm(s): Structured Testing Group (STG) | Intervention Type: DEVICE; Name: Accu-Chek Aviva Glucose Meter; Assigned to Arm(s): Active Control Group (ACG), Structured Testing Group (STG)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Midazolam for Continuous Sedation of Ventilated Patients in Intensive Care Unit
Brief Summary: Patients in ICU who need help with their breathing are put onto a machine called a ventilator and are also given a medicine, called a sedative, which helps them to sleep and makes them more comfortable. Midazolam is a sedative that is routinely used for these purposes.

For most patients the aim of sedation is to make them sleepy but still able to respond to nursing staff (light sedation)

Dexmedetomidine is a new sedative for use in intensive care and in this clinical study, dexmedetomidine is compared to midazolam. It is thought that dexmedetomidine might be slightly better at allowing patients to be sleepy but still respond to people around them. It also does not appear to affect patient's breathing. the purpose of this study is to test whether dexmedetomidine really does have these advantages compared to midazolam.

in this study we hope to show that: dexmedetomidine is at least as good as midazolam in helping patients to sleep better and making them more comfortable, and that they are able to co-operate better with the staff treating them, and that patients treated with dexmedetomidine require a shorter time on the ventilator than those treated with midazolam.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): 2
B: Arm Label: Balanced Anesthesia; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: NoNarc TIVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIVA NoNarc | Intervention Type: DRUG; Name: TIVA NoNarc; Assigned to Arm(s): NoNarc TIVA
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl 9/00 | Arm Label: dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Intervention Type: DRUG; Name: NaCl 9/00; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): dexmedetomidine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Midazolam for Continuous Sedation of Ventilated Patients in Intensive Care Unit
Brief Summary: Patients in ICU who need help with their breathing are put onto a machine called a ventilator and are also given a medicine, called a sedative, which helps them to sleep and makes them more comfortable. Midazolam is a sedative that is routinely used for these purposes.

For most patients the aim of sedation is to make them sleepy but still able to respond to nursing staff (light sedation)

Dexmedetomidine is a new sedative for use in intensive care and in this clinical study, dexmedetomidine is compared to midazolam. It is thought that dexmedetomidine might be slightly better at allowing patients to be sleepy but still respond to people around them. It also does not appear to affect patient's breathing. the purpose of this study is to test whether dexmedetomidine really does have these advantages compared to midazolam.

in this study we hope to show that: dexmedetomidine is at least as good as midazolam in helping patients to sleep better and making them more comfortable, and that they are able to co-operate better with the staff treating them, and that patients treated with dexmedetomidine require a shorter time on the ventilator than those treated with midazolam.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): 2
B: Intervention Type: PROCEDURE; Name: SAT: Spontaneous Awakening Trial; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: SBT: Spontaneous Breathing Trial; Assigned to Arm(s): N/A
C: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
D: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)
Brief Summary: The purpose of this study is to determine the effectiveness of commercially available kefir on preventing antibiotic-associated diarrhea compared to placebo in children ages 1-5.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Kefir; Type: EXPERIMENTAL; Interventions: Other: Kefir | Intervention Type: OTHER; Name: Kefir; Assigned to Arm(s): Kefir | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: OTHER; Name: Biventricular pacing post cardiac surgery; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: BIO-K+ CL-1285; Type: ACTIVE_COMPARATOR; Interventions: Other: BIO-K+ CL-1285® | Arm Label: BIO-K+ CL-1285® & placebo; Type: OTHER; Interventions: Other: BIO-K+ CL-1285®, Other: Placebo | Intervention Type: OTHER; Name: BIO-K+ CL-1285®; Assigned to Arm(s): BIO-K+ CL-1285, BIO-K+ CL-1285® & placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): BIO-K+ CL-1285® & placebo, Placebo
D: Arm Label: Saccharomyces boulardii; Type: ACTIVE_COMPARATOR; Interventions: Drug: Saccharomyces boulardii | Arm Label: Microcristallin cellulose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Microcristallin cellulose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK)
Brief Summary: The purpose of this study is to determine the effectiveness of commercially available kefir on preventing antibiotic-associated diarrhea compared to placebo in children ages 1-5.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri (DSM 17938); Assigned to Arm(s): N/A
B: Arm Label: Probiotics; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Probiotic capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic capsules; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Kefir; Type: EXPERIMENTAL; Interventions: Other: Kefir | Intervention Type: OTHER; Name: Kefir; Assigned to Arm(s): Kefir | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus GG | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus GG; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Ergonovine-Oxytocin Versus Oxytocin During Cesarean Delivery Following Failure to Progress in Labour
Brief Summary: Despite of marked improvements in clinical management, early postpartum hemorrhage(PPH)remains a significant contributor to maternal morbidity and mortality both in developing countries and in hospitals equipped with all that modern medicine has to offer. This complication is amongst the most challenging that a clinician will face in the obstetric patient. Prevention, early recognition and prompt appropriate intervention are the keys to minimizing the impact of PPH on women's health.

Patients undergoing Cesarean sections following failure to progress in labor are at great risk for PPH and should theoretically benefit from an additional uterotonic agent. This study will be conducted to define whether the addition of ergonovine maleate to oxytocin, administered in a prophylactic way, reduces blood loss during Cesarean section for failure to progress in labor.


Options:
A: Arm Label: oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: oxytocin3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): oxytocin, oxytocin2, oxytocin3
B: Arm Label: tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: transamin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: transamin; Assigned to Arm(s): tranexamic acid
C: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Folic Acid; Type: PLACEBO_COMPARATOR; Interventions: Drug: Folic Acid | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Folic Acid
D: Intervention Type: DRUG; Name: Methyl-Ergonovine-Oxytocin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Ergonovine-Oxytocin Versus Oxytocin During Cesarean Delivery Following Failure to Progress in Labour
Brief Summary: Despite of marked improvements in clinical management, early postpartum hemorrhage(PPH)remains a significant contributor to maternal morbidity and mortality both in developing countries and in hospitals equipped with all that modern medicine has to offer. This complication is amongst the most challenging that a clinician will face in the obstetric patient. Prevention, early recognition and prompt appropriate intervention are the keys to minimizing the impact of PPH on women's health.

Patients undergoing Cesarean sections following failure to progress in labor are at great risk for PPH and should theoretically benefit from an additional uterotonic agent. This study will be conducted to define whether the addition of ergonovine maleate to oxytocin, administered in a prophylactic way, reduces blood loss during Cesarean section for failure to progress in labor.


Options:
A: Arm Label: tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: transamin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: transamin; Assigned to Arm(s): tranexamic acid
B: Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): N/A
C: Arm Label: Syntocinon; Type: ACTIVE_COMPARATOR; Interventions: Drug: Syntocinon | Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Syntocinon; Assigned to Arm(s): Syntocinon | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
D: Intervention Type: DRUG; Name: Methyl-Ergonovine-Oxytocin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuous Terlipressin Versus Vasopressin Infusion in Septic Shock. A Randomized, Controlled, Pilot Trial. "THE TERLIVAP STUDY"
Brief Summary: The purpose of this study is to determine whether: A)the continuous infusion ultra-low dose of terlipressin (1.3 micrograms/kg/h) is able to stabilize hemodynamic in patients with septic shock, reducing the risk of adverse effects related to the bolus dose.B)the continuous infusion ultra-low dose of terlipressin may be use in lieu of vasopressin.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Early Goal Directed Therapy (EGDT) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Protocolized Standard Care (PSC) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual Care (UC) | Intervention Type: PROCEDURE; Name: Early Goal Directed Therapy (EGDT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Protocolized Standard Care (PSC); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Usual Care (UC); Assigned to Arm(s): 3
B: Arm Label: Angiotensin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Angiotensin II | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Angiotensin II | Intervention Type: DRUG; Name: Angiotensin II; Assigned to Arm(s): Angiotensin, Control
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vasopressin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Norepinephrine | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Norepinephrine; Assigned to Arm(s): 3
D: Arm Label: continuous terlipressin; Type: EXPERIMENTAL; Interventions: Drug: continuous infusion of terlipressin | Arm Label: vasopressin; Type: EXPERIMENTAL; Interventions: Drug: Arginine vasopressin | Arm Label: terlipressin bolus dose; Type: EXPERIMENTAL; Interventions: Drug: terlipressin bolus administration | Intervention Type: DRUG; Name: continuous infusion of terlipressin; Assigned to Arm(s): continuous terlipressin | Intervention Type: DRUG; Name: Arginine vasopressin; Assigned to Arm(s): vasopressin | Intervention Type: DRUG; Name: terlipressin bolus administration; Assigned to Arm(s): terlipressin bolus dose

Answer: C